Effect of vitamin D supplementation on the pregnancy outcomes

Evaluation the efficacy of vitamin D supplementation during pregnancy on maternal and newborn vitamin D status and pregnancy outcomes compared with control group

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016090329675N1

Enrollment

126

Registered

2016-09-25

Start date

2016-10-11

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Pre-eclampsia. Condition 2: Vitamin D status in pregnant women and cord blood. Condition 3: Getational Diabetes Mellitus. Condition 4: Preterm delivery. Condition 5: Abortion. Pre-eclampsia, unspecified E55: Vitamin D deficiency Diabetes mellitus arising in pregnancy (Gestational diabetes mellitus NOS) Preterm labour and delivery Spontaneous abortion

Interventions

Intervention 1: Control group: Current supplementation during pregnancy (Iron, Folic acid, Multi-vitamin). Intervention 2: Intervention group 1: Current supplementation during pregnancy (Iron, Folic a

Prevention

Control group: Current supplementation during pregnancy (Iron, Folic acid, Multi-vitamin)

Intervention group 1: Current supplementation during pregnancy (Iron, Folic acid, Multi-vitamin) + 1000 IU/d vitamin D

Intervention group 2: Current supplementation during pregnancy (Iron, Folic acid, Multi-vitamin) + 2000 IU/d vitamin D

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Pregnant women aged at 18-40 years and their newborns, Singleton pregnancy. Exclusion criteria: Multiple pregnancy, Diagnosis any kind of diseases including renal, hepatic, and other disorders which could influence vitamin D metabolism during the study, Chronic hypertension, Receiving vitamin D or calcium supplements within the last three months, On any medication which could potentially influence vitamin D metabolism (notably estrogens, and calcitonin) within the last three months, Newborns with congenital anomalies.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Vitamin D concentration of pregnant women serum. Timepoint: Baseline and after the intervention. Method of measurement: High performance liquid chromatography (HPLC).;Vitamin D concentration of Cord blood. Timepoint: At birth. Method of measurement: High performance liquid chromatography (HPLC).	—

Secondary

Measure	Time frame
Growth indices of newborns. Timepoint: After Birth. Method of measurement: Infant's Records.;Preterm delivery. Timepoint: At less than 37 weeks of gestational age. Method of measurement: Pregnant women Records.;Abortion. Timepoint: During the first 28 weeks of pregnancy. Method of measurement: Pregnant women Records.;Gestational diabetes. Timepoint: At the gestational age of 24-28 weeks. Method of measurement: Pregnant women Records.;Preeclampsia. Timepoint: At the gestational age of 24-28 weeks. Method of measurement: Pregnant women Records.	—

Measure

Time frame

Growth indices of newborns. Timepoint: After Birth. Method of measurement: Infant's Records.;Preterm delivery. Timepoint: At less than 37 weeks of gestational age. Method of measurement: Pregnant women Records.;Abortion. Timepoint: During the first 28 weeks of pregnancy. Method of measurement: Pregnant women Records.;Gestational diabetes. Timepoint: At the gestational age of 24-28 weeks. Method of measurement: Pregnant women Records.;Preeclampsia. Timepoint: At the gestational age of 24-28 weeks. Method of measurement: Pregnant women Records.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSoudabe Motamed

National Nutrition and Food Technology Research Institute, Faculty of Nutrition Sciences and Food Te

s_motamed@sbmu.ac.ir; smotamed2010@gmail.com+98 21 2237 6471

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026